The most recent Top 50 Healthcare, Pharmaceutical and Biotechnology Focused Hedge Fund list has been released, revealing that the top hedge funds now manage $70 billion in U.S. equity assets. Larry Robbins' Glenview Capital Management has retained the top spot, once again, with $13.2 billion in equity assets under management. Glenview Capital's sector favorites include Thermo Fisher Scientific (NYSE:TMO), HCA Holdings Inc (NYSE:HCA) and Health Management Associates (NYSE:HMA). Over the last quarter, Glenview Capital notably increased its bets on Tenet Healthcare (NYSE:THC) and Aetna Inc (NYSE:AET).
Other top investors that lead the Top Healthcare, Pharma and Biotech Hedge Fund List include #2 OrbiMed Advisors, #3 Baker Bros. Advisors LLC, and #4 Partner Fund Management. The largest investments for OrbiMed Advisors, which is run by industry stalwart Samuel Isaly, include Gilead Sciences Inc (NASDAQ:GILD), Biogen Idec Inc (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). Notably, Isaly's firm entered and bought up large stakes in Relypsa Inc (NASDAQ:RLYP), Perrigo Co (NASDAQ:PRGO) and Acceleron Pharma (NASDAQ:XLRN) over the quarter, while also increasing its stakes in Abbvie Inc (NYSE:ABBV) and Celgene Corp (NASDAQ:CELG).
Baker Bros. Advisors' top positions include Pharmacyclics Inc (NASDAQ:PCYC), Seattle Genetics (NASDAQ:SGEN) and Incyte Corp (NASDAQ:INCY), while Partner Fund Management's top industry picks include Gilead Sciences Inc (GILD), Bristol-Myers Squibb (BMY) and Actavis Inc (ACT).
Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms' overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker's Hedge Fund Portal.